A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.

Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.

After two months of zero confirmed domestic coronavirus cases in Beijing, a new cluster of 50 fuels fears of a second wave and prompts authorities to speed up readiness through a first vaccine launch.

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.